Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Freselestat SCHEMBL6748609 | 1.00 | ELANE (1.00) | ELANE | |
| Freselestat SCHEMBL7004023 | 1.00 | ELANE (1.00) | ELANE | |
| SCHEMBL7009087 | 0.93 | ELANE (1.00) | ELANE | |
| SCHEMBL5728743 | 0.92 | ELANE (0.86) | ELANE | |
| SCHEMBL7006422 | 0.92 | ELANE (1.00) | ELANE | |
| SCHEMBL7005603 | 0.92 | ELANE (1.00) | ELANE | |
| SCHEMBL7005967 | 0.92 | ELANE (1.00) | ELANE | |
| SCHEMBL7004970 | 0.92 | ELANE (1.00) | ELANE | |
| SCHEMBL29197371 | 0.88 | ELANE (0.79) | ELANE | |
| SCHEMBL7202424 | 0.88 | ELANE (1.00) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023998-A1 | Novel crystals of 1,3,4-oxadiazole derivatives, process for producing the crystals and medicines containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-05 | — | — | US | claimed |
| US-20030216324-A1 | Airway mucus secretion inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| US-20030212115-A1 | Remedies for inflammatory bowel diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-13 | — | — | US | claimed |
| EP-1323420-A1 | REMEDIES FOR INFLAMMATORY BOWEL DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-1323419-A1 | AIRWAY MUCUS SECRETION INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-1318150-A1 | NOVEL CRYSTALS OF 1,3,4-OXADIAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE CRYSTALS AND MEDICINES CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Ono Pharmaceutical Co. (JP) | 2003-06-11 | — | — | EP | claimed |
| US-20020119985-A1 | Serine protease inhibitors | CORTECH, INC. | 2002-08-29 | — | — | US | claimed |
| US-20040023998-A1 | Novel crystals of 1,3,4-oxadiazole derivatives, process for producing the crystals and medicines containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-20040023998-A1 | Novel crystals of 1,3,4-oxadiazole derivatives, process for producing the crystals and medicines containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6656910-B2 | Serine protease inhibitors | CORTECH, INC. | 2003-12-02 | — | — | US | disclosed |
| US-6656911-B2 | Oxadiazole ring structure peptoids which are useful as inhibitors of serine proteases | CORTECH, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20030216324-A1 | Airway mucus secretion inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| US-20030212115-A1 | Remedies for inflammatory bowel diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1219608-A1 | PYRIMIDINE DERIVATIVES, PROCESS FOR PREPARING THE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002014310-A1 | 2-[5-AMINO-6-OXO-2-PHENYL-1,6-DIHYDRO-1-PYRIMIDYL]-N-[1-(2-[5-t-BUTYL-1,3,4-OXADIAZOLYL]CARBONYL)-2-(R,S)-METHYLPROPYL]ACETAMIDE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-02-21 | — | — | WO | disclosed |
| EP-1162199-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-6150334-A | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE STRUCTURES WHICH ARE USEFUL AS INHIBITORS OF SERINE PROTEASES, INCLUDING HUMAN NEUTROPHIL ELASTASE | CORTECH, INC. | 2000-11-21 | — | — | US | disclosed |
| US-6015791-A | Serine protease inhibitors-cycloheptane derivatives | CORTECH INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-6001811-A | TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPSIS, MULTIPLE ORGAN FAILURE | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5998379-A | USEFUL AS INHIBITORS OF SERINE PROTEASES, IN PARTICULAR HUMAN NEUTROPHIL ELASTASE, TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK, AND MYOCARDIAL ISCHEMIA-REPERFUSION INJURY | CORTECH INC. (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119985-A1 | Serine protease inhibitors | PRSS1, SERPINB1, SERPINE1 | ELANE 61/4885 |
| US-20030212115-A1 | Remedies for inflammatory bowel diseases | NOS3, TPMT, NOS2 | ELANE 588/4885 |
| US-20040023998-A1 | Novel crystals of 1,3,4-oxadiazole derivatives, process for producing the crystals and medicines containing the same as the active ingredient | PKD2, MGAT1, XDH | ELANE 1818/4885 |
| US-20030216324-A1 | Airway mucus secretion inhibitors | MUC1, CFTR, SERPINB1 | ELANE 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.